The UK and US have hammered out a significant commercial pact that will ensure no duties on British medicine exports going into the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the public health system. This pledge guarantees that tariffs on these key exports will be held at nothing for a duration of three years.
This agreement follows recent threats to significantly raise duties on branded pharmaceutical products, with potential rates discussed as high as double the cost.
"This agreement between the Britain bolsters the worldwide climate for innovative medicines and introduces much-needed equity to transatlantic drug exports," a release noted.
Commercial Significance
Pharmaceuticals represent one of the UK's largest exports to the US, which is easily the largest destination for large companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This value represented a significant portion of total UK exports in that span.
"This agreement secures work, increases investment and paves the way for the UK to become a worldwide center for life sciences," a minister stated.
Specific NHS Changes
The agreement includes several notable changes from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to control costs will be restricted at 15%. Previously, repayments exceeded twenty percent.
Industry Background
This agreement comes amid a ongoing tension between the drug companies and the ministers over spending levels and regulatory access.
These tensions were exacerbated by claims that US patients were charged significantly more for the equivalent treatments than people in the other developed nations.
Recently, several large drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward American operations.
One official publicly accepted that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
